Cystic Fibrosis

Cystic Fibrosis

As per Global Insight services' assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Cystic Fibrosis - pipeline landscape globally. Cystic Fibrosis Pipeline Insight, 2023" report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.

Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies :

Cystic Fibrosis (CF) is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time. In people with CF, a defective gene causes a thick, sticky buildup of mucus in the lungs, pancreas, and other organs. In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage, and eventually, respiratory failure. In the pancreas, the mucus prevents the release of digestive enzymes that the body needs to break down food and absorb vital nutrients.

In cystic fibrosis, a defect (mutation) in CFTR gene, changes a protein that regulates the movement of salt in and out of cells. Many different defects can occur in the gene. The type of gene mutation is associated with the severity of the condition.

Report Highlights

Global Insight Service's, Cystic Fibrosis - Drug Pipeline Landscape, 2023 report provides an overview of the Cystic Fibrosis pipeline drugs. This report covers detailed insights on Cystic Fibrosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Cystic Fibrosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Read more about Cystic Fibrosis Pipeline Insight here:


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Key Players

• 4D Molecular Therapeutics
• AbbVie
• AlgiPharma AS
• Aridis Pharmaceuticals, Inc.
• Armata Pharmaceuticals, Inc
• Atlantic Healthcare
• BiomX, Inc.
• Calithera Biosciences, Inc
• Chiesi Farmaceutici S.p.A.
• Eloxx Pharmaceuticals, Inc.
• Enterprise Therapeutics Ltd
• First Wave Bio, Inc.
• Galapagos NV
• Insmed Incorporated
• Ionis Pharmaceuticals, Inc.
• Krystal Biotech, Inc
• Laurent Pharmaceuticals Inc
• Mast Therapeutics, Inc

Buy Now :

Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -

- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail:[email protected]
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.

Source link